Skip to main content
Clinical Trials/NCT06751069
NCT06751069
Recruiting
N/A

Home-based Pulmonary Rehabilitation and Health Coaching in Patients With Fibrotic Interstitial Lung Disease: A Prospective Pragmatic Randomized Waitlist-Controlled Trial

Mayo Clinic4 sites in 1 country460 target enrollmentMarch 3, 2025

Overview

Phase
N/A
Intervention
Not specified
Conditions
Lung Fibrosis
Sponsor
Mayo Clinic
Enrollment
460
Locations
4
Primary Endpoint
King's Brief Interstitial Lung Disease (K- BILD)
Status
Recruiting
Last Updated
last month

Overview

Brief Summary

The purpose of this clinical trial is to determine the impact of a home-based pulmonary rehabilitation program with health coaching on patient-reported respiratory-related quality of life and physical activity, as compared to usual care in patients with fibrotic interstitial lung disease.

Detailed Description

The fibrotic interstitial lung diseases (f-ILD) are a group of progressive and debilitating lung diseases sharing characteristics of lung scarring on imaging and restricted breathing on pulmonary function testing (PFT). Symptoms include shortness of breath, cough, and fatigue, eventually leading to deconditioning and poor quality of life. While medical therapies are available for slowing or stopping the loss of lung function, only pulmonary rehabilitation (PR) has shown a positive impact on patient-reported shortness of breath and physical activity. Unfortunately, PR may not be widely available to all patients, and some patients may become too ill to participate in traditional center-based programs. A primary hypothesis is that modifying the content, delivery, and setting for PR in patients with f-ILD to improve access or ease of use and supporting behavior change through a health coach will have a measurable and sustained positive impact on patient well-being and quality of life as compared to no participation or non-use.

Registry
clinicaltrials.gov
Start Date
March 3, 2025
End Date
September 30, 2030
Last Updated
last month
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Teng Moua

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • IInclusion Criteria:
  • F-ILD diagnosis, any disease subtype, active or prior medical treatment
  • \>10% fibrosis on CT imaging
  • mMRC dyspnea score \>1
  • All racial or ethnic categories, including non-English speakers (professional translators will be engaged to support screening, enrollment, and study participation)

Exclusion Criteria

  • Inability to walk (orthopedic/neurologic/cardiac limitation causing immobility)
  • Cognitive impairment or inability to understand and follow instructions
  • Traditional center-based PR completed within 3 months of initial study recruitment
  • Transition to hospice or end-of-life care at the time of screening
  • Acute exacerbation at the time of screening

Outcomes

Primary Outcomes

King's Brief Interstitial Lung Disease (K- BILD)

Time Frame: Baseline, end of intervention (3 months), and 3 months post-intervention

Respiratory-related quality of life questionnaire

Physical activity as measured by change in mean number of steps per day

Time Frame: Baseline, end of intervention (3 months), and 3 months post-intervention

Mean number of steps as measured by Actigraph monitor over 5-7 days

Secondary Outcomes

  • Modified Medical Research Council (mMRC)(Baseline, end of intervention (3 months), and 3 months post-intervention)
  • Living with Pulmonary Fibrosis (L-PF)-Symptoms and Impacts Questionnaire(Baseline, end of intervention (3 months), and 3 months post-intervention)
  • FACIT Fatigue Scale(Baseline, end of intervention (3 months), and 3 months post-intervention)
  • Leicester Cough Questionnaire (LCQ)(Baseline, end of intervention (3 months), and 3 months post-intervention)

Study Sites (4)

Loading locations...

Similar Trials